Upstream Bio, Inc. (UPB) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Waltham, MA, United States. El CEO actual es E. Rand Sutherland.
UPB tiene fecha de IPO 2024-10-11, 52 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $537.13M.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
